Psychedelic Medication

Enveric Biosciences (NASDAQ:ENVB) reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024. "We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug...

This article was originally published on Microdose and appears here with permission. Recently, there has been an exciting discussion in LinkedIn posts and Microdose PsyCap events regarding the presumed declining status and dire future of the psychedelic medication industry. In summary, these are...